A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Edward B Garon; Byoung Chul Cho; Alexander Luft; Jorge Alatorre-Alexander; Sarayut Lucien Geater; Dmytro Trukhin; Sang-We Kim; Grygorii Ursol; Maen Hussein; Farah Louise Lim; Cheng-Ta Yang; Luiz Henrique Araujo; Haruhiro Saito; Niels Reinmuth; Milena Kohlmann; Caitlin Lowery; Helen Mann; Solange Peters; Tony S Mok; Melissa L Johnson

doi:10.1016/j.cllc.2024.03.003

YUHSpace

BROWSE

62 144

Cited 0 times in

Cited 6 times in

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Authors: Edward B Garon ; Byoung Chul Cho ; Alexander Luft ; Jorge Alatorre-Alexander ; Sarayut Lucien Geater ; Dmytro Trukhin ; Sang-We Kim ; Grygorii Ursol ; Maen Hussein ; Farah Louise Lim ; Cheng-Ta Yang ; Luiz Henrique Araujo ; Haruhiro Saito ; Niels Reinmuth ; Milena Kohlmann ; Caitlin Lowery ; Helen Mann ; Solange Peters ; Tony S Mok ; Melissa L Johnson

Citation: CLINICAL LUNG CANCER, Vol.25(3) : 266-273.e5, 2024-05

Journal Title: CLINICAL LUNG CANCER

ISSN: 1525-7304

Issue Date: 2024-05

MeSH: Antibodies, Monoclonal* / administration & dosage ; Antibodies, Monoclonal* / therapeutic use ; Antibodies, Monoclonal, Humanized* / administration & dosage ; Antibodies, Monoclonal, Humanized* / therapeutic use ; Antineoplastic Combined Chemotherapy Protocols* / therapeutic use ; B7-H1 Antigen* / antagonists & inhibitors ; B7-H1 Antigen* / metabolism ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; Carcinoma, Non-Small-Cell Lung* / pathology ; Female ; Humans ; Lung Neoplasms* / drug therapy ; Lung Neoplasms* / pathology ; Male ; Treatment Outcome

Keywords: Clinical trial ; Cytotoxic T-lymphocyte-associated antigen 4 ; Immune checkpoint inhibitor ; Immunotherapy ; Programmed cell death ligand-1